Articles tagged with: Telintra
Headline, News »
The American Society of Hematology (ASH) 2011 annual meeting is currently being held in San Diego. This article will summarize the myelodysplastic syndromes-related highlights from Saturday, the first full day of the conference, and Sunday, the second day of the meeting.
Day 1
Saturday started off with an education session on myelodysplastic syndromes (MDS) that consisted of three talks. The program was repeated in the afternoon.
The day ended with a large poster session, during which study results from hundreds of blood disorder-related studies were displayed on big posters…
Headline, News »
Results from a Phase 2 clinical trial indicate that extended dosing of Telintra improves blood cell counts and reduces dependence on red blood cell transfusions in patients with lower-risk myelodysplastic syndromes.
The study’s authors found that a lower dosage given for an additional week during each treatment cycle improved red blood cell counts for a longer time and caused fewer side effects.
“Telintra is the first oral GST P1-inhibitor that has been shown to reduce or eliminate the need for red blood cell transfusions, which potentially would be a significant…
News »
Telik Begins Phase 2 Trial Of Telintra For MDS – Earlier this month, the pharmaceutical company Telik announced the start of a Phase 2 clinical trial of its investigational drug Telintra (ezatiostat HCl) in patients with myelodysplastic syndromes (MDS). The trial will investigate the efficacy and safety of Telintra in MDS patients with a deletion in chromosome 5 who are resistant to or have relapsed after treatment with Revlimid (lenalidomide). The main aim of the study will be to determine what percentage of participants achieve transfusion independence or a reduction in transfusions. For more information, please see the Telik press release.
Webinar About MDS Treatments – The Aplastic Anemia & MDS International Foundation (AA&MDSIF) will be holding a webinar this Wednesday, June 29, about currently approved treatments for MDS. Dr. Gail Roboz, Director of the Leukemia Program at Weill Medical College of Cornell University, will speak about Vidaza (azacitidine), Dacogen (decitabine), and Revlimid, including their efficacy, side effects, and dosing schedule. The webinar will run from 3 p.m. to 4:15 pm ET and will include a question and answer session. For additional information or to register, please see the AA&MDSIF website.
Free One-Day Conference For MDS Patients In Seattle – The MDS Foundation is sponsoring a forum for MDS patients and their families on July 9 at the Renaissance Seattle Hotel. A support group discussion will be held in the morning, and Dr. Joachim Deeg of the Fred Hutchinson Cancer Research Center will give a presentation on new therapies and treatment options in the afternoon. There is no cost for the event, but registration is required. For more information or to register, please see the MDS Foundation website.
For a more detailed listing of upcoming MDS-related events, please check the MDS Beacon Events Calendar.
Headline, News »
On December 5, the second full day of the American Society of Hematology meeting, the sessions about myelodysplastic syndromes included a series of talks in the afternoon and a poster session in the evening.
The afternoon session featured presentations about the molecular mechanisms of myelodysplastic syndromes (MDS). Many of the talks were about genes and genetic mutations that play a role in MDS to help physicians better understand the disease and how to target it with treatment.
In the evening, results from a number of clinical trials for current MDS…
Featured, Headline, News »
The experimental drug Telintra improves blood counts and is well-tolerated in patients with lower-risk myelodysplastic syndromes, according to a Phase 2 trial conducted at multiple American cancer centers.
The study authors also found that patients taking Telintra (ezatiostat hydrochloride) who had prior Revlimid (lenalidomide) treatment showed better results than patients previously treated with Vidaza (azacitidine) or Dacogen (decitabine).
The trial results were presented by Dr. Azra Raza of Columbia University Medical Center in New York City during a poster session on Sunday at the 2010 meeting of the American Society…